Internal Medicine
Latest news
360 articles · 20 / page
Five-Year Durability of Etranacogene Dezaparvovec: Redefining the Long-term Management of Hemophilia B
The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine proph
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro
B-Cell Depletion Meets TPO-RA: Ianalumab and Eltrombopag Redefine Treatment Success in Immune Thrombocytopenia
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering
Riboflavin and Blood Pressure: Evidence Remains Uncertain Despite Genetic Promise
Cochrane review shows uncertain effects of riboflavin on blood pressure, highlighting a need for larger and better-quality trials.
Aspirin in the Healthy Elderly: ASPREE’s Clear Message — No Benefit, Higher Bleeding, and Unexpected Cancer Signal
ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑relat
Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha
Mobile Integrated Health vs Transitions of Care in Heart Failure: Insights from the Mighty-Heart Trial
A large clinical trial compared Mobile Integrated Health with standard care coordination for heart failure patients after hospital discharge, finding no significant overall benefits but highlighting potential age-related effects.
Remote Cognitive Training, Structured Rehabilitation and tDCS Failed to Improve Self‑Reported Cognitive Symptoms in Long COVID: Results from a 5‑Arm Phase 2 Randomized Trial
A multicenter phase 2 randomized trial found no differential benefit of adaptive computerized cognitive training, structured cognitive rehabilitation, or transcranial direct current stimulation (tDCS) versus active comparators for self‑repo
The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women
In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, indepe
Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy
A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.
Quadpill or Dual Therapy for hypertension? Emerging Consensus After QUARTET — What Clinicians and Patients Should Know
Summarizes emerging expert consensus on ultra‑low‑dose quadruple antihypertensive therapy (the “quadpill”) after QUARTET and related evidence, with practical recommendations and caveats for clinical use.
Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD
A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.
Remote Ischemic Conditioning Lowers Systolic Blood Pressure in Uncontrolled Essential Hypertension: Results of the RICBP‑EH Randomised Trial
A single‑centre randomized trial in China found that 7 days of remote ischemic conditioning (RIC) reduced average systolic BP by about 4.8 mm Hg versus sham in patients with essential hypertension (SBP ≥140 mm Hg), with good tolerability.
Home‑Delivered DASH Groceries Lower Blood Pressure and LDL in Black Urban Residents — but Benefits Fade After Support Ends
The GoFresh randomized trial found that 12 weeks of home‑delivered DASH‑patterned groceries plus dietitian counseling reduced systolic BP by 3.4 mm Hg versus cash stipends and lowered LDL; effects were not sustained three months after the i
Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial
The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.
Each Hour Sitting Counts: Sedentary Time Linked to Lower Intrinsic Capacity and Faster Decline in Older Adults
In a prospective Beijing cohort (BLINDSCE), each additional hour of daily sedentary time was associated with a 1.18-point lower baseline intrinsic capacity and a 0.48-point greater decline over 1 year, suggesting sedentary behavior is a mod
How Much Aerobic Exercise Is Enough to Reduce Depression in Patients with Chronic Illness? A Dose–Response Meta-analysis Points to an Achievable Target
A meta-analysis of 36 RCTs (n=2,500) found aerobic exercise significantly reduces depressive symptoms in people with chronic illness (Hedges’ g -0.73). A weekly dose of ≈405 MET‑min (≈120–135 min of moderate aerobic activity) reaches a mini
Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts
A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.
Understanding Nonceliac Gluten/Wheat Sensitivity: A Global Perspective on a Common But Complex Condition
Nonceliac gluten/wheat sensitivity affects about 1 in 10 people worldwide, with strong links to female sex, psychological distress, and irritable bowel syndrome. This article explores its prevalence, symptoms, challenges in diagnosis, and i
Weekly Amylin Agonist Eloralintide Produces 10–21% Weight Loss at 48 Weeks in Phase 2 Trial
In a 48‑week multicenter phase 2 trial, weekly amylin receptor agonist eloralintide produced dose‑dependent mean weight loss of 9.4%–20.9% versus 0.4% for placebo, with improved waist circumference and cardiometabolic markers; tolerability
Browse by specialty
Open language-specific specialty feeds and department pages.